The goal of this study is to learn if mesenchymal stem cell therapy (treatment group) can effectively treat autoimmune diseases, when compared to normal saline (given to placebo group). The primary outcome measures will be clinical improvement based on the respective disease specific clinical scores, normalization of T-lymphocyte subsets and \> 50% reduction in disease specific antibody titres. The study will also document the type and frequency of any adverse event or side effects, reported by or seen in any of the trial participants. Patients in treatment group will receive single session of MSC therapy and placebo group will receive 0.9% saline solution. The participants will be followed at 3 and 6 months.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Primary Outcome Measures for RA
Timeframe: Day 0, Weeks 12, 24, 48
Primary Outcome Measures for RA
Timeframe: Day 0, Weeks 12, 24, 48
Primary Outcome Measures for RA
Timeframe: Day 0, Weeks 12, 24, 48
Primary Outcome Measures for RA
Timeframe: Day 0, Weeks 12, 24, 48
Primary Outcome Measures for RA
Timeframe: Day 0, Weeks 12, 24, 48
Primary Outcome Measures for RA
Timeframe: Day 0, Weeks 12, 24, 48
Primary Outcome Measures for Systemic lupus erythematosus
Timeframe: Day 0, Weeks 12, 24, 48
Primary Outcome Measures for systemic sclerosis
Timeframe: Day 0, Weeks 12, 24, 48
Primary Outcome Measures for systemic sclerosis
Timeframe: Day 0, Weeks 12, 24, 48
Primary outcome measures in ankylosing spondlitis
Timeframe: Week 16
Primary Outcome Measure for dermatomyositis
Timeframe: Day 0, Weeks 12, 24, 48